Latest Sonic Healthcare (ASX:SHL) News

Small-cap resources led the week’s biggest moves, but sharp falls in Bounty Oil and Nyrada showed how quickly investors can sell when funding and deal terms remain uncertain.
Gold, copper, rare earths and takeover activity supplied the strongest gains, while several companies still need more cash before they can deliver their plans.

Biotech funding and regulatory setbacks drove the week’s biggest healthcare share moves, while larger companies delivered stronger earnings and deal activity. Telix’s proposed ITM takeover, Ramsay’s demerger plans and a mixed group of clinical updates kept investors focused on cash, approvals and sales.

Sonic Healthcare delivered a strong FY2026, with underlying net profit up 17% to A$621 million and dividends rising to A$1.08 per share. The next test is whether US efficiencies, LADR synergies and organic growth can offset Swiss fee cuts, a delayed UK contract ramp-up and heavier investment demands.

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.

Sonic Healthcare has reported a robust half-year performance, with revenue climbing 16.6% to A$5.45 billion and net profit rising 10.9%, underpinned by organic growth and key acquisitions. The company maintains its full-year guidance amid ongoing US business rationalisation.

Sonic Healthcare has reaffirmed its FY2026 EBITDA guidance with up to 13% growth, reported solid FY2025 financial results, and announced a strategic acquisition in Germany alongside notable sustainability progress.

Sonic Healthcare announces a major leadership transition with Dr Colin Goldschmidt retiring after 32 years as CEO, succeeded by Dr Jim Newcombe. The company also appoints Evangelos Kotsopoulos as Chief Operating Officer to support its global growth ambitions.

Sonic Healthcare has delivered solid FY 2025 results, meeting EBITDA guidance with 5% organic revenue growth and setting the stage for up to 19% EPS growth in FY 2026, driven by strategic acquisitions and operational synergies.

Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.

Sonic Healthcare Limited has announced an ordinary dividend of AUD 0.63 per share for the first half of 2025, with a 35% franking component and payment scheduled for mid-September.

Sonic Healthcare reported solid FY2025 results with revenue up 7.6% and a steady profit increase, while declaring a 63-cent final dividend. The company’s recent German acquisition and ongoing synergy efforts set the stage for robust earnings growth in FY2026.